文献速递临床试验与 GCP

非选择性β受体阻滞剂或安慰剂用于食管静脉曲张一级预防(BOPPP):一项随机对照试验的研究方案

Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of oesophageal varices: study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2024-04-16

BOPPP试验是一项在英格兰、苏格兰、威尔士和北爱尔兰进行的实用性、多中心、安慰剂对照、三盲随机对照试验,计划纳入740例肝硬化伴小食管静脉曲张且从未出血的患者,1:1随机接受卡维地洛6.25 mg(每日一次或两次)或匹配安慰剂,治疗36个月,主要结局为首次失代偿事件时间。

要点

  • BOPPP试验旨在评估卡维地洛能否预防或减少肝硬化伴小食管静脉曲张患者的失代偿。
  • 主要复合结局包括静脉曲张出血、腹水、肝性脑病、自发性细菌性腹膜炎等。
  • 目前对早期门脉高压阶段使用非选择性β受体阻滞剂是否有益存在临床均势。

核心结论

  • BOPPP试验旨在研究卡维地洛在肝硬化伴小食管静脉曲张患者中的临床和成本效益,以确定该非选择性β受体阻滞剂能否预防或减少肝失代偿。
  • 目前对于在肝硬化较早阶段(门脉高压早期)使用非选择性β受体阻滞剂治疗是否有益存在临床均势。

研究设计与样本

  • BOPPP试验是一项实用性、多中心、安慰剂对照、三盲、随机对照试验,在英格兰、苏格兰、威尔士和北爱尔兰进行。
  • 计划纳入740例年龄18岁及以上、肝硬化伴小食管静脉曲张且从未出血的患者,来自英国55家医院。
  • 患者按1:1比例随机接受卡维地洛6.25 mg(一种非选择性β受体阻滞剂)或匹配安慰剂,每日一次或两次,治疗36个月。

主要发现

  • 主要结局为首次失代偿事件的时间,复合结局包括静脉曲张出血、新发或加重的腹水、新发或加重的肝性脑病、自发性细菌性腹膜炎、肝肾综合征、Child-Pugh分级增加1级或MELD评分增加5分以及肝相关死亡。
  • 次要结局包括进展至中或大食管静脉曲张、胃、十二指肠或异位静脉曲张的发生、参与者生活质量、医疗保健费用和无移植生存。

关键数值与推荐

  • 卡维地洛剂量为6.25 mg,每日一次或两次,治疗36个月。
  • 主要复合结局中MELD评分增加5分或Child-Pugh分级增加1级。

临床怎么用

  • 若试验取得阳性结果,预计卡维地洛的使用将广泛推广,并制定路径以在初级保健中标准化该药物的给药。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Liver disease is within the top five causes of premature death in adults. Deaths caused by complications of cirrhosis continue to rise, whilst deaths related to other non-liver disease areas are declining. Portal hypertension is the primary sequelae of cirrhosis and is associated with the development of variceal haemorrhage, ascites, hepatic encephalopathy and infection, collectively termed hepatic decompensation, which leads to hospitalisation and mortality. It remains uncertain whether administering a non-selective beta-blocker (NSBB), specifically carvedilol, at an earlier stage, i.e. when oesophageal varices are small, can prevent VH and reduce all-cause decompensation (ACD). METHODS/DESIGN: The BOPPP trial is a pragmatic, multicentre, placebo-controlled, triple-blinded, randomised controlled trial (RCT) in England, Scotland, Wales and Northern Ireland. Patients aged 18 years or older with cirrhosis and small oesophageal varices that have never bled will be recruited, subject to exclusion criteria. The trial aims to enrol 740 patients across 55 hospitals in the UK. Patients are allocated randomly on a 1:1 ratio to receive either carvedilol 6.25 mg (a NSBB) or a matched placebo, once or twice daily, for 36 months, to attain adequate power to determine the effectiveness of carvedilol in preventing or reducing ACD. The primary outcome is the time to first decompensating event. It is a composite primary outcome made up of variceal haemorrhage (VH, new or worsening ascites, new or worsening hepatic encephalopathy (HE), spontaneous bacterial peritonitis (SBP), hepatorenal syndrome, an increase in Child-Pugh grade by 1 grade or MELD score by 5 points, and liver-related mortality. Secondary outcomes include progression to medium or large oesophageal varices, development of gastric, duodenal, or ectopic varices, participant quality of life, healthcare costs and transplant-free survival. DISCUSSION: The BOPPP trial aims to investigate the clinical and cost-effectiveness of carvedilol in patients with cirrhosis and small oesophageal varices to determine whether this non-selective beta-blocker can prevent or reduce hepatic decompensation. There is clinical equipoise on whether intervening in cirrhosis, at an earlier stage of portal hypertension, with NSBB therapy is beneficial. Should the trial yield a positive result, we anticipate that the administration and use of carvedilol will become widespread with pathways developed to standardise the administration of the medication in primary care. ETHICS AND DISSEMINATION: The trial has been approved by the National Health Service (NHS) Research Ethics Committee (REC) (reference number: 19/YH/0015). The results of the trial will be submitted for publication in a peer-reviewed scientific journal. Participants will be informed of the results via the BOPPP website ( www.boppp-trial.org ) and partners in the British Liver Trust (BLT) organisation. TRIAL REGISTRATION: EUDRACT reference number: 2018-002509-78. ISRCTN reference number: ISRCTN10324656. Registered on April 24 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Patel VC, McPhail MJ, Uddin R, et al. Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of oesophageal varices: study protocol for a randomised controlled trial. Trials. 2024. PMID: 38627804. doi:10.1186/s13063-024-08063-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。